Normalized Parameters of Dynamic Contrast-Enhanced Perfusion MRI and DWI-ADC for Differentiation between Posttreatment Changes and Recurrence in Head and Neck Cancer

References

1. 1.↵
   1. Wong LY,
   2. Wei WI,
   3. Lam LK, et al

   . Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003;25:953–59 doi:10.1002/hed.10310 pmid:14603456

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Hermans R

   . Posttreatment imaging in head and neck cancer. Eur J Radiol 2008;66:501–11 doi:10.1016/j.ejrad.2008.01.021 pmid:18328660

   CrossRefPubMed
3. 3.
   1. Saito N,
   2. Nadgir RN,
   3. Nakahira M, et al

   . Posttreatment CT and MR imaging in head and neck cancer: what the radiologist needs to know. Radiographics 2012;32:1261–82 doi:10.1148/rg.325115160 pmid:22977017

   CrossRefPubMed
4. 4.↵
   1. Baba A,
   2. Ojiri H,
   3. Ikeda K, et al

   . Essentials on oncological imaging: postoperative computed tomography and magnetic resonance imaging of oral tongue cancer. Can Assoc Radiol J 2018;69:458–67 doi:10.1016/j.carj.2018.08.001 pmid:30390963

   CrossRefPubMed
5. 5.↵
   1. Aiken AH,
   2. Rath TJ,
   3. Anzai Y, et al

   . ACR Neck Imaging Reporting and Data Systems (NI-RADS): a White Paper of the ACR NI-RADS Committee. J Am Coll Radiology 2018;15:1097–108 doi:10.1016/j.jacr.2018.05.006 pmid:29983244

   CrossRefPubMed
6. 6.↵
   1. Newbold K,
   2. Castellano I,
   3. Charles-Edwards E, et al

   . An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:29–37 doi:10.1016/j.ijrobp.2008.07.039 pmid:19036529

   CrossRefPubMed
7. 7.↵
   1. Jansen JF,
   2. Carlson DL,
   3. Lu Y, et al

   . Correlation of a priori DCE-MRI and 1H-MRS data with molecular markers in neck nodal metastases: initial analysis. Oral Oncol 2012;48:717–22 doi:10.1016/j.oraloncology.2012.02.001 pmid:22366441

   CrossRefPubMed
8. 8.↵
   1. Bernstein JM,
   2. Kershaw LE,
   3. Withey SB, et al

   . Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer. Oral Oncol 2015;51:508–13 doi:10.1016/j.oraloncology.2015.01.013 pmid:25700703

   CrossRefPubMed
9. 9.↵
   1. Ng S,
   2. Lin C,
   3. Chan S, et al

   . Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One 2013;8:e72230 doi:10.1371/journal.pone.0072230 pmid:23951300

   CrossRefPubMed
10. 10.↵
    1. Chikui T,
    2. Kitamoto E,
    3. Kawano S, et al

    . Pharmacokinetic analysis based on dynamic contrast-enhanced MRI for evaluating tumor response to preoperative therapy for oral cancer. J Magn Reson Imaging 2012;36:589–97 doi:10.1002/jmri.23704 pmid:22649040

    CrossRefPubMed
11. 11.↵
    1. Tomura N,
    2. Omachi K,
    3. Sakuma I, et al

    . Dynamic contrast-enhanced magnetic resonance imaging in radiotherapeutic efficacy in the head and neck tumors. Am J Otolaryngol 2005;26:163–67 doi:10.1016/j.amjoto.2004.11.011 pmid:15858770

    CrossRefPubMed
12. 12.↵
    1. Ishiyama M,
    2. Richards T,
    3. Parvathaneni U, et al

    . Dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer: differentiation of new H&N cancer, recurrent disease, and benign post-treatment changes. Clin Imaging 2015;39:566–70 doi:10.1016/j.clinimag.2015.01.016 pmid:25778388

    CrossRefPubMed
13. 13.↵
    1. Furukawa M,
    2. Parvathaneni U,
    3. Maravilla K, et al

    . Dynamic contrast-enhanced MR perfusion imaging of head and neck tumors at 3 Tesla. Head Neck 2013;35:923–29 doi:10.1002/hed.23051 pmid:22887003

    CrossRefPubMed
14. 14.↵
    1. Semiz Oysu A,
    2. Ayanoglu E,
    3. Kodalli N, et al

    . Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck. Clin Imaging 2005;29:307–12 doi:10.1016/j.clinimag.2005.01.024 pmid:16153535

    CrossRefPubMed
15. 15.↵
    1. Ota Y,
    2. Liao E,
    3. Kurokawa R, et al

    . Diffusion-weighted and dynamic contrast-enhanced MRI to assess radiation therapy response for head and neck paragangliomas. J Neuroimaging 2021;31:1035–43 doi:10.1111/jon.12875 pmid:34002429

    CrossRefPubMed
16. 16.↵
    1. Ailianou A,
    2. Mundada P,
    3. De Perrot T, et al

    . MRI with DWI for the detection of posttreatment head and neck squamous cell carcinoma: why morphologic MRI criteria matter. AJNR Am J Neuroradiol 2018;39:748–55 doi:10.3174/ajnr.A5548 pmid:29449279

    Abstract/FREE Full Text
17. 17.↵
    1. Jajodia A,
    2. Aggarwal D,
    3. Chaturvedi AK, et al

    . Value of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changes. Oral Oncol 2019;96:89–96 doi:10.1016/j.oraloncology.2019.06.037 pmid:31422219

    CrossRefPubMed
18. 18.↵
    1. Tshering Vogel DW,
    2. Zbaeren P,
    3. Geretschlaeger A, et al

    . Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers. Eur Radiol 2013;23:562–69 doi:10.1007/s00330-012-2596-x pmid:22865270

    CrossRefPubMed
19. 19.
    1. Hwang I,
    2. Choi SH,
    3. Kim YJ, et al

    . Differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma: application of high b-value diffusion-weighted imaging. AJNR Am J Neuroradiol 2013;34:2343–48 doi:10.3174/ajnr.A3603 pmid:23811978

    Abstract/FREE Full Text
20. 20.↵
    1. Baba A,
    2. Kurokawa R,
    3. Kurokawa M, et al

    . ADC for differentiation between benign post-treatment changes and recurrence in head and neck cancer: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2022;43:442–47 doi:10.3174/ajnr.A7431

    Abstract/FREE Full Text
21. 21.↵
    1. Koontz NA,
    2. Wiggins RH

    . Differentiation of benign and malignant head and neck lesions with diffusion tensor imaging and DWI. AJR Am J Roentgenol 2017;208:1110–15 doi:10.2214/AJR.16.16486 pmid:28245145

    CrossRefPubMed
22. 22.↵
    1. Mouridsen K,
    2. Christensen S,
    3. Gyldensted L, et al

    . Automatic selection of arterial input function using cluster analysis. Magn Reson Med 2006;55:524–31 doi:10.1002/mrm.20759 pmid:16453314

    CrossRefPubMed
23. 23.↵
    1. Donato H,
    2. França M,
    3. Candelária I, et al

    . Liver MRI: from basic protocol to advanced techniques. Eur J Radiol 2017;93:30–39 doi:10.1016/j.ejrad.2017.05.028 pmid:28668428

    CrossRefPubMed
24. 24.↵
    1. Ding X,
    2. Xu H,
    3. Zhou J, et al

    . Reproducibility of normalized apparent diffusion coefficient measurements on 3.0-T diffusion-weighted imaging of normal pancreas in a healthy population. Medicine (Baltimore 2019;98:e15104 doi:10.1097/MD.0000000000015104 pmid:30946375

    CrossRefPubMed
25. 25.↵
    1. Isles MG,
    2. McConkey C,
    3. Mehanna HM

    . A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210–22 doi:10.1111/j.1749-4486.2008.01688.x pmid:18559026

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Kim S,
    2. Roh J,
    3. Seung J, et al

    . 18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. Eur J Cancer 2017;72:62–70 doi:10.1016/j.ejca.2016.11.009 pmid:28027517

    CrossRefPubMed